Background: Burn injury leads to a hypercatabolic response and ultimately muscle wasting with drastic implications for recovery of bodily functions, patient’s quality of life (QoL), and long-term survival. Several treatment options target the body’s initial stress response, but pharmacological approaches to specifically address muscle protein metabolism have only been poorly investigated. Objective: The aim of this study was to assess the role of myostatin and follistatin in burn injury and its possible implications in muscle wasting syndrome. Methods: We harvested serum from male patients within 48 h and again 9–12 months after severe burn injury (>20% of total body surface area). By means of myoblast cultures, immunohistochemistry, immunoblotting, and scratch assay, the role of myostatin and its implications in post-burn muscle metabolism and myoblast proliferation and differentiation was analyzed. Results: We were able to show increased proliferative and myogenic capacity, decreased myostatin, decreased SMAD 2/3, and elevated follistatin concentrations in human skeletal myoblast cultures with serum conditioned medium of patients in the acute phase of burn injury and conversely a reversed situation in patients in the chronic phase of burn injury. Thus, there is a biphasic response to burn trauma, initiated by an anabolic state and followed by long-term hypercatabolism. Conclusion: We conclude that the myostatin signaling pathway plays an important regulative role in burn-associated muscle wasting and that blockade of myostatin could prove to be a valuable treatment approach improving the rehabilitation process, QoL, and long-term survival after severe burn injury.

1.
Porter
C
,
Tompkins
RG
,
Finnerty
CC
,
Sidossis
LS
,
Suman
OE
,
Herndon
DN
.
The metabolic stress response to burn trauma: current understanding and therapies
.
Lancet
.
2016
Oct
;
388
(
10052
):
1417
26
.
[PubMed]
0140-6736
2.
Pereira
C
,
Murphy
K
,
Jeschke
M
,
Herndon
DN
.
Post burn muscle wasting and the effects of treatments
.
Int J Biochem Cell Biol
.
2005
Oct
;
37
(
10
):
1948
61
.
[PubMed]
1357-2725
3.
Williams
FN
,
Herndon
DN
,
Jeschke
MG
.
The hypermetabolic response to burn injury and interventions to modify this response
.
Clin Plast Surg
.
2009
Oct
;
36
(
4
):
583
96
.
[PubMed]
0094-1298
4.
Wallner
C
,
Jaurich
H
,
Wagner
JM
,
Becerikli
M
,
Harati
K
,
Dadras
M
, et al
Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2
.
Sci Rep
.
2017
Aug
;
7
(
1
):
9878
.
[PubMed]
2045-2322
5.
Lin
J
,
Arnold
HB
,
Della-Fera
MA
,
Azain
MJ
,
Hartzell
DL
,
Baile
CA
.
Myostatin knockout in mice increases myogenesis and decreases adipogenesis
.
Biochem Biophys Res Commun
.
2002
Mar
;
291
(
3
):
701
6
.
[PubMed]
0006-291X
6.
Egerman
MA
,
Cadena
SM
,
Gilbert
JA
,
Meyer
A
,
Nelson
HN
,
Swalley
SE
, et al
GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration
.
Cell Metab
.
2015
Jul
;
22
(
1
):
164
74
.
[PubMed]
1550-4131
7.
Zhou
C
,
Liu
Y
,
Yao
Y
,
Zhou
S
,
Fang
N
,
Wang
W
, et al
β-blockers and volatile anesthetics may attenuate cardioprotection by remote preconditioning in adult cardiac surgery: a meta-analysis of 15 randomized trials
.
J Cardiothorac Vasc Anesth
.
2013
Apr
;
27
(
2
):
305
11
.
[PubMed]
1053-0770
8.
Loumaye
A
,
de Barsy
M
,
Nachit
M
,
Lause
P
,
Frateur
L
,
van Maanen
A
, et al
Role of Activin A and myostatin in human cancer cachexia
.
J Clin Endocrinol Metab
.
2015
May
;
100
(
5
):
2030
8
.
[PubMed]
0021-972X
9.
Costelli
P
,
Muscaritoli
M
,
Bonetto
A
,
Penna
F
,
Reffo
P
,
Bossola
M
, et al
Muscle myostatin signalling is enhanced in experimental cancer cachexia
.
Eur J Clin Invest
.
2008
Jul
;
38
(
7
):
531
8
.
[PubMed]
0014-2972
10.
Soriano-Arroquia
A
,
Clegg
PD
,
Molloy
AP
,
Goljanek-Whysall
K
.
Preparation and Culture of Myogenic Precursor Cells/Primary Myoblasts from Skeletal Muscle of Adult and Aged Humans
.
J Vis Exp
.
2017
Feb
;
•••
(
120
):
[PubMed]
1940-087X
11.
Ashraf
MI
,
Ebner
M
,
Wallner
C
,
Haller
M
,
Khalid
S
,
Schwelberger
H
, et al
A p38MAPK/MK2 signaling pathway leading to redox stress, cell death and ischemia/reperfusion injury
.
Cell Commun Signal
.
2014
Jan
;
12
(
1
):
6
.
[PubMed]
1478-811X
12.
Glass
DJ
.
Skeletal muscle hypertrophy and atrophy signaling pathways
.
Int J Biochem Cell Biol
.
2005
Oct
;
37
(
10
):
1974
84
.
[PubMed]
1357-2725
13.
Powers
SK
,
Kavazis
AN
,
DeRuisseau
KC
.
Mechanisms of disuse muscle atrophy: role of oxidative stress
.
Am J Physiol Regul Integr Comp Physiol
.
2005
Feb
;
288
(
2
):
R337
44
.
[PubMed]
0363-6119
14.
Du
J
,
Wang
X
,
Miereles
C
,
Bailey
JL
,
Debigare
R
,
Zheng
B
, et al
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions
.
J Clin Invest
.
2004
Jan
;
113
(
1
):
115
23
.
[PubMed]
0021-9738
15.
Yousuf
Y
,
Jeschke
MG
,
Shah
A
,
Sadri
AR
,
Datu
AK
,
Samei
P
, et al
The response of muscle progenitor cells to cutaneous thermal injury
.
Stem Cell Res Ther
.
2017
Oct
;
8
(
1
):
234
.
[PubMed]
1757-6512
16.
Amthor
H
,
Hoogars
WM
. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
17.
Amthor
H
,
Otto
A
,
Macharia
R
,
McKinnell
I
,
Patel
K
.
Myostatin imposes reversible quiescence on embryonic muscle precursors
.
Dev Dyn
.
2006
Mar
;
235
(
3
):
672
80
.
[PubMed]
1058-8388
18.
Wang
Q
,
McPherron
AC
.
Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation
.
J Physiol
.
2012
May
;
590
(
9
):
2151
65
.
[PubMed]
0022-3751
19.
Diaz
EC
,
Herndon
DN
,
Porter
C
,
Sidossis
LS
,
Suman
OE
,
Børsheim
E
.
Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns
.
Burns
.
2015
Jun
;
41
(
4
):
649
57
.
[PubMed]
0305-4179
20.
Hart
DW
,
Wolf
SE
,
Mlcak
R
,
Chinkes
DL
,
Ramzy
PI
,
Obeng
MK
, et al
Persistence of muscle catabolism after severe burn
.
Surgery
.
2000
Aug
;
128
(
2
):
312
9
.
[PubMed]
0039-6060
21.
Han
HQ
,
Mitch
WE
.
Targeting the myostatin signaling pathway to treat muscle wasting diseases
.
Curr Opin Support Palliat Care
.
2011
Dec
;
5
(
4
):
334
41
.
[PubMed]
1751-4258
22.
Benny Klimek
ME
,
Aydogdu
T
,
Link
MJ
,
Pons
M
,
Koniaris
LG
,
Zimmers
TA
.
Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia
.
Biochem Biophys Res Commun
.
2010
Jan
;
391
(
3
):
1548
54
.
[PubMed]
0006-291X
23.
Zimmers
TA
,
Davies
M V
,
Koniaris
LG
,
Haynes
P
,
Esquela
AF
,
Tomkinson
KN
, et al
:
Induction of Cachexia in Mice by Systemically Administered Myostatin.
Science (80-)
2002
;296:1486–1488.
24.
Lang
CH
,
Silvis
C
,
Nystrom
G
,
Frost
RA
:
Regulation of myostatin by glucocorticoids after thermal injury.
FASEB J
2001
[cited 2018 Jun 16];15:1807–9.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.